Atherosclerosis, 91 (1991) 285–287
© 1991 Elsevier Scientific Publishers Ireland, Ltd. All rights reserved 0021-9150/91/$03.50

Author Index (Vol. 91)

Arakawa, K., see Zhang, B. (91) 277
Araki, G., see Homma, Y. (91) 145
Aston, C.E., see Kamboh, M.I. (91) 25
Avogaro, P., Cazzolato, G. and Bittolo-Bon, G.
Some questions concerning a small, more electronegative LDL circulating in human plasma (91) 163

Betteridge, D.J., see Jay, R.H. (91) 117
Bhakdi, S., see Seifert, P.S. (91) 155
Bittolo-Bon, G., see Avogaro, P. (91) 163
Brun, S., see Gris, J.C. (91) 247
Brunschwig, C., see Gris, J.C. (91) 247

Carmelli, D., see Lamon-Fava, S. (91) 97
Castelli, W.P., see Lamon-Fava, S. (91) 97
Cazzolato, G., see Avogaro, P. (91) 163
Christian, J.C., see Lamon-Fava, S. (91) 97
Clair, R.W.S., see Sulistiyani, (91) 123
Conlan, M.G., see Folsom, A.R. (91) 191
Cooper, J.P. and Newby, A.C.
Monocyte adhesion to human saphenous vein in vitro (91) 85

Davis, C.E., see Folsom, A.R. (91) 191
De Servi, S., see Ricevuti, G. (91) 1
Ditschuneit, H., see Stange, E.F. (91) 257
Ditschuneit, H.H., see Stange, E.F. (91) 257
Dróżdż, M., see Gmiński, J. (91) 185
Dudman, N.P.B., Hicks, C., Wang, J. and Wilcken, D.E.L.
Human arterial endothelial cell detachment in vitro: its promotion by homocysteine and cysteine (91) 77
Durham, S.K., see Kowala, M.C. (91) 35

Fabsitz, R.R., see Lamon-Fava, S. (91) 97
Ferrell, R.E., see Kamboh, M.I. (91) 25
Folsom, A.R., Wu, K.K., Davis, C.E., Conlan, M.G., Sorlie, P.D. and Szklo, M.
Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors (91) 191

Gallagher, J.J., see Maher, V.M.G. (91) 73
Gmiński, J., Dróżdż, M., Ulfig-Maślanka, R. and Najda, J.
Evaluation of elastin metabolism in children from families with high risk of atherosclerosis (91) 185
Goto, Y., see Homma, Y. (91) 145
Gris, J.C., Schved, J.F., Brun, S., Brunschwig, C., Petris, I., Lassonnery, M., Martinez, P. and Sarlat, C.
Venous occlusion and chronic cigarette smoking: dose-dependent decrease in the measurable release of tissue-type plasminogen activator and von Willebrand factor (91) 247

Hagihara, H., Nomoto, A., Mutoh, S., Yamaguchi, I. and Ono, T.
Role of inflammatory responses in initiation of atherosclerosis: effects of anti-inflammatory drugs on cuff-induced leukocyte accumulation and intimal thickening of rabbit carotid artery (91) 107
Hamman, R.F., see Kamboh, M.I. (91) 25
Harders-Spengel, K., see Wade, D.P. (91) 63
Hawley, M.S., see Mangion, D.M. (91) 137
Hicks, C., see Dudman, N.P.B. (91) 77
Hirata, K., see Zhang, B. (91) 277
Homma, Y., Ohshima, K., Yamaguchi, H., Nakamura, H., Araki, G. and Goto, Y.
Effects of eicosapentaenoic acid on plasma lipoprotein subfractions and activities of lecithin:cholesterol acyltransferase and lipid transfer protein (91) 145
Howard, B.V., see Patti, L. (91) 15
Humphries, S.E., see Renges, H.-H. (91) 267

Iyengar, S., see Kamboh, M.I. (91) 25

Jay, R.H., McCarthy, S.N., Rampling, M.W. and Betteridge, D.J.
Blood rheology and fibrinogen in children with familial hypercholesterolaemia (91) 117
Jimenez, D., see Lamon-Fava, S. (91) 97
Johansson, J., Mölgaard, J. and Olsson, A.G.
Plasma high density lipoprotein particle size alteration by simvastatin treatment in patients with hypercholesterolaemia (91) 175
Jouni, Z.E., see Shi, F. (91) 217

Kamanna, V.S., see Kirschenbaum, M.A. (91) 241
Kamboh, M.I., Hamman, R.F., Iyengar, S., Aston, C.E. and Ferrell, R.E.
Apolipoprotein A-IV polymorphism, and its role in determining variation in lipoprotein-lipid, glucose and insulin levels in normal and non-insulin-dependent diabetic individuals (91) 25
Kirschenbaum, M.A., Roh, D.D. and Kamanna, V.S.
Effect of nifedipine on renal microvascular cholesterol accumulation and prostacyclin biosynthesis in cholesterol-fed rabbits (91) 241

Knight, B.L., see Wade, D.P. (91) 63
Kowala, M.C., Nunnari, J.J., Durham, S.K. and Nicolosi, R.J.
Doxazosin and cholestyramine similarly decrease fatty streak formation in the aortic arch of hyperlipidemic hamsters (91) 35

Lamon-Fava, S., Jimenez, D., Christian, J.C., Fabsitz, R.R., Reed, T., Carmelli, D., Castelli, W.P., Ordovas, J.M., Wilson, P.W.F. and Schaefer, E.J.
The NHLBI Twin Study: heritability of apolipoprotein A-I, B, and low density lipoprotein subclasses and concordance for lipoprotein(a) (91) 97
Lassonnery, M., see Gris, J.C. (91) 247
Liu, R., see Zhang, B. (91) 277

Maher, V.M.G., Gallagher, J.J., Thompson, G.R. and Myant, N.B.
Response to cholesterol-lowering drugs in familial defective apolipoprotein B-100 (91) 73
Mangion, D.M., Hawley, M.S. and Norcliffe, D.
Lower limb arterial disease: assessment of risk factors in an elderly population (91) 137
Marmot, M.G., see Renges, H.-H. (91) 267
Martinez, P., see Gris, J.C. (91) 247
Mazzone, A., see Ricevuti, G. (91) 1
McCarthy, S.N., see Jay, R.H. (91) 117
McKeigue, P.M., see Renges, H.-H. (91) 267
McNamara, D.J., see Shi, F. (91) 217
Messner, M., see Seifert, P.S. (91) 155
Mölgaard, J., see Johansson, J. (91) 175
Morimatsu, M., see Yanagi, H. (91) 207
Mutoh, S., see Hagihara, H. (91) 107
Myant, N.B., see Maher, V.M.G. (91) 73

Nagase, H., see Yanagi, H. (91) 207
Najda, J., see Gmiński, J. (91) 185
Nakamura, H., see Homma, Y. (91) 145
Newby, A.C., see Cooper, J.P. (91) 85
Nicolosi, R.J., see Kowala, M.C. (91) 35
Nomoto, A., see Hagihara, H. (91) 107
Norcliffe, D., see Mangion, D.M. (91) 137
Nunnari, J.J., see Kowala, M.C. (91) 35

Ohshima, K., see Homma, Y. (91) 145
Olsson, A.G., see Johansson, J. (91) 175
Ono, T., see Hagihara, H. (91) 107
Ordovas, J.M., see Lamon-Fava, S. (91) 97
Osenbrügge, M., see Stange, E.F. (91) 257
Owens, R.T. and Wagner, W.D.
Proteoglycans produced by cholesterol-enriched macrophages bind plasma low density lipoprotein (91) 229

Pasotti, D., see Ricevuti, G. (91) 1
Patti, L., Swinburn, B., Riccardi, G., Rivellese, A.A. and Howard, B.V.
Alterations in very low density lipoprotein subfractions in normotriglyceridemic non-insulin-dependent diabetics (91) 15
Petris, I., see Gris, J.C. (91) 247

Rampling, M.W., see Jay, R.H. (91) 117
Reed, T., see Lamon-Fava, S. (91) 97
Reimann, F., see Stange, E.F. (91) 257
Renges, H.-H., Wile, D.B., McKeigue, P.M., Marmot, M.G. and Humphries, S.E.
Apolipoprotein B gene polymorphisms are associated with lipid levels in men of South Asian descent (91) 267
Riccardi, G., see Patti, L. (91) 15
Ricevuti, G., Mazzone, A., Pasotti, D., De Servi, S. and Specchia, G.
Role of granulocytes in endothelial injury in coronary heart disease in humans (91) 1
Rivellese, A.A., see Patti, L. (91) 15
Roh, D.D., see Kirschenbaum, M.A. (91) 241
Roth, I., see Seifert, P.S. (91) 155
Rustan, M., see Stange, E.F. (91) 257

Saku, K., see Zhang, B. (91) 277
Sarlat, C., see Gris, J.C. (91) 247
Sasaguri, Y., see Yanagi, H. (91) 207
Schaefer, E.J., see Lamon-Fava, S. (91) 97
Schneider, A., see Stange, E.F. (91) 257
Schved, J.F., see Gris, J.C. (91) 247
Seifert, P.S., Messner, M., Roth, I. and Bhakdi, S.
Analysis of complement C3 activation products in human atherosclerotic lesions (91) 155
Shi, F., Jouni, Z.E. and McNamara, D.J.
Reduced regulatory capacity of low density lipoproteins from patients with coronary artery disease (91) 217
Sorlie, P.D., see Folsom, A.R. (91) 191
Soutar, A.K., see Wade, D.P. (91) 63
Specchia, G., see Ricevuti, G. (91) 1
Stange, E.F., Osenbrügge, M., Rustan, M., Reimann, F., Schneider, A., Ditschuneit, H.H. and Ditschuneit, H.
Inhibition of HMG-CoA reductase in mononuclear cells during gemfibrozil treatment (91) 257
Sugama, K., see Yanagi, H. (91) 207
Sulistiyani, and Clair, R.W.S.
The method of isolation of primary cells and their subculture influences the expression of LDL receptors on pigeon and chicken embryo cells in culture (91) 123
Swinburn, B., see Patti, L. (91) 15
Szklo, M., see Folsom, A.R. (91) 191

Tam, S.-P.
Effects of gemfibrozil and ketoconazole on human apolipoprotein AI, B and E levels in two hepatoma cell lines, HepG2 and Hep3B (91) 51
Tateishi, K., see Zhang, B. (91) 277
Thompson, G.R., see Maher, V.M.G. (91) 73

Ulfig-Maślanka, R., see Gmiński, J. (91) 185

Wade, D.P., Knight, B.L., Harders-Spengel, K. and Soutar, A.K.
Detection and quantitation of apolipoprotein(a) mRNA in human liver and its relationship with plasma lipoprotein(a) concentration (91) 63

Wagner, W.D., see Owens, R.T. (91) 229
Wang, J., see Dudman, N.P.B. (91) 77
Wilcken, D.E.L., see Dudman, N.P.B. (91) 77
Wile, D.B., see Renges, H.-H. (91) 267
Wilson, P.W.F., see Lamon-Fava, S. (91) 97
Wu, K.K., see Folsom, A.R. (91) 191

Yamaguchi, H., see Homma, Y. (91) 145
Yamaguchi, I., see Hagihara, H. (91) 107
Yamamoto, K., see Zhang, B. (91) 277

Yanagi, H., Sasaguri, Y., Sugama, K., Morimatsu, M. and Nagase, H.
Production of tissue collagenase (matrix metalloproteinase 1) by human aortic smooth muscle cells in response to platelet-derived growth factor (91) 207

Zhang, B., Saku, K., Hirata, K., Liu, R., Tateishi, K., Yamamoto, K. and Arakawa, K.
Insulin resistance observed in WHHL rabbits (91) 277

Atherosclerosis, 91 (1991) 289–290
© 1991 Elsevier Scientific Publishers Ireland, Ltd. All rights reserved 0021-9150/91/$03.50

Subject Index (Vol. 91)

Acyl-CoA:cholesterol acyltransferase, (91) 217
Alpha-1 adrenergic blockers, (91) 35
Anti-elastin antibodies, (91) 185
Apo B/E receptor, (91) 217
Apolipoprotein A-I, (91) 97; (91) 175
Apolipoprotein A-IV, (91) 25
Apolipoprotein(a) mRNA, (91) 63
Apolipoprotein(a) phenotype, (91) 63
Apolipoprotein B, (91) 97
Apolipoprotein B gene, (91) 267
Apolipoproteins, (91) 51
ARIC study, (91) 191
Arteriosclerosis, (91) 85
Atherogenesis, (91) 77
Atherosclerosis, (91) 35; (91) 107; (91) 163; (91) 185; (91) 207; (91) 229; (91) 241
Atherosclerosis: VLDL, VLDL subfractions, (91) 15

Blood coagulation factors, (91) 191
Blood pressure, (91) 35
Blood viscosity, Plasma viscosity, (91) 117

Cell culture, (91) 85
Children, (91) 117
Cholesterol, (91) 241
Cholesterol-lowering drugs, (91) 73
Cholesterol synthesis, (91) 257
Cholestyramine, (91) 35
Complement degradation, (91) 155
Connective tissue degradation, (91) 207
Coronary artery bypass graft, (91) 85
Coronary artery disease, (91) 1; (91) 97
Coronary disease, (91) 191
Coronary heart disease, (91) 267
Cytochrome *P*-450, (91) 51

Diabetes, (91) 15
Doppler ultrasound, (91) 137
Doxazosin, (91) 35

Eicosapentaenoic acid, (91) 145
Elastase-like activity, (91) 185
Elastin-derived peptides, (91) 185
Elderly, (91) 137
Endopeptidases, (91) 207
Endothelial cell, (91) 107
Endothelial cell detachment, (91) 77
Endothelium, (91) 85

Factor VII, (91) 191
Familial defective apolipoprotein B-100, (91) 73
Familial hypercholesterolaelmia (FH), (91) 175
Fibrinogen, (91) 117; (91) 191
Fibronectin, (91) 77
Foam cell, (91) 35

Gemfibrozil, (91) 257
Glomerulosclerosis, (91) 241
Granulocytes, (91) 1

HDL cholesterol, (91) 267
HDL gradient gel electrophoresis (gge) subclasses, (91) 175
Heritability, (91) 97
HL-60 cells, (91) 217
HMG-CoA reductase inhibitor, (91) 175
Homocystinuria, (91) 77
Human liver, (91) 63
3-Hydroxy-3-methylglutaryl coenzyme A reductase, (91) 257
Hypercholesterolaemia, (91) 117
Hypercholesterolaelmia, (91) 175
Hyperlipoproteinemia, (91) 257
Hypolipidemic drugs, (91) 51

Inflammation, (91) 155
Inflammatory responses, (91) 107
Intimal thickening, (91) 107
Ion-exchange HPLC, (91) 163

Kidney, (91) 241
Kringle 4 repeats, (91) 63

LDL subfraction, (91) 145
Lecithin:cholesterol acyltransferase, (91) 145
Leukocyte, (91) 85
Leukocyte adhesion, (91) 107
Leukotrienes, (91) 1
Lipid peroxidation, (91) 163
Lipid transfer protein, (91) 145
Lipoprotein(a), (91) 63; (91) 97
Lipoprotein composition, (91) 15
Lipoprotein-lipid levels, (91) 25
Lipoprotein subfractions, (91) 145

Low density lipoprotein, (91) 97; (91) 163; (91) 229
Low density lipoprotein degradation, (91) 217
Low density lipoprotein receptor, (91) 257
Lower limb arterial disease, (91) 137

Macrophage, (91) 35
Macrophages, (91) 229
Metabolism of elastin, (91) 185
Microvasculature, (91) 241
Modified LDL, (91) 163
Multivariate analysis, (91) 137

Nifedipine, (91) 241
Non-insulin-dependent diabetes, (91) 25

Oil red O, (91) 35

Plasma cholesterol, (91) 35
Plasma lipoproteins, (91) 217
Polymorphism, (91) 25
Prostacyclin, (91) 241
Prostaglandins, (91) 241
Proteoglycan–LDL complex, (91) 229
Proteoglycans, (91) 229

Red cell aggregation, (91) 117
Red cell deformability, (91) 117
RFLPs, (91) 267
Risk factors, (91) 137

Simvastatin, (91) 175
Sluicing assay, (91) 77
South Asians (Punjabi Sikhs), (91) 267
Sterol synthesis, (91) 217

Tissue-type plasminogen activator, (91) 247
Tobacco, (91) 247
Total cholesterol, (91) 267
Twins, (91) 97

Vascular disease, (91) 77
Vascular pathology, (91) 155
Venous occlusion, (91) 247
Vitamin E, (91) 163
Von Willebrand factor, (91) 247